Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review

被引：0
作者：
Min Jia
Xu Gao
Yan Zhang
Michael Hoffmeister
Hermann Brenner
机构：
[1] German Cancer Research Center (DKFZ),Division of Clinical Epidemiology and Aging Research
[2] German Cancer Consortium (DKTK),undefined
来源：
Clinical Epigenetics | 2016年 / 8卷
关键词：
Colorectal cancer; CpG island methylator phenotype; Prognosis; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Contradictory results were reported for the prognostic role of CpG island methylator phenotype (CIMP) among colorectal cancer (CRC) patients. Differences in the definitions of CIMP were the most common explanation for these discrepancies. The aim of this systematic review was to give an overview of the published studies on CRC prognosis according to the different definitions of CIMP. A systematic literature search was performed in MEDLINE and ISI Web of Science for articles published until 3 April 2015. Data extraction included information about the study population, the definition of CIMP, and investigated outcomes. Thirty-six studies were included in this systematic review. Among them, 30 studies reported the association of CIMP and CRC prognosis and 11 studies reported the association of CIMP with survival after CRC therapy. Overall, 16 different definitions of CIMP were identified. The majority of studies reported a poorer prognosis for patients with CIMP-positive (CIMP+)/CIMP-high (CIMP-H) CRC than with CIMP-negative (CIMP−)/CIMP-low (CIMP-L) CRC. Inconsistent results or varying effect strengths could not be explained by different CIMP definitions used. No consistent variation in response to specific therapies according to CIMP status was found. Comparative analyses of different CIMP panels in the same large study populations are needed to further clarify the role of CIMP definitions and to find out how methylation information can best be used to predict CRC prognosis and response to specific CRC therapies.
引用
收藏
相关论文
共 320 条
[11]  
Ahuja N(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 e1000100-802
[12]  
Ohe-Toyota M(2002)Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands Gut 51 797-70
[13]  
Herman JG(2005)Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res 65 6063-6
[14]  
Baylin SB(2008)Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases Cancer Res 68 8541-64
[15]  
Issa JP(2008)Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability Arch Pathol Lab Med 132 958-13
[16]  
Jover R(2008)Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation Pathol Int 58 104-45
[17]  
Nguyen TP(2009)Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas Dis Colon Rectum 52 1039-94
[18]  
Perez-Carbonell L(2009)Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers Virchows Arch 455 485-6
[19]  
Zapater P(2009)CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer Gut 58 90-8
[20]  
Paya A(2009)Microsatellite instability and survival in rectal cancer Cancer Causes Control 20 1763-204
12345678910